

## HEMATOPOIESIS AND STEM CELLS

## Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus

Monica Cusan,<sup>1-3</sup> Naidu M. Vegi,<sup>4</sup> Medhanie A. Mulaw,<sup>4</sup> Shiva Bamezai,<sup>4</sup> Lisa M. Kaiser,<sup>4</sup> Aniruddha J. Deshpande,<sup>5</sup> Philipp A. Greif,<sup>1,2,6,7</sup> Leticia Quintanilla-Fend,<sup>8</sup> Stefanie Göllner,<sup>9</sup> Carsten Müller-Tidow,<sup>9</sup> Keith R. Humphries,<sup>10</sup> Scott A. Armstrong,<sup>3</sup> Wolfgang Hiddemann,<sup>1,2</sup> Michaela Feuring-Buske,<sup>4,11</sup> and Christian Buske<sup>4</sup>

<sup>1</sup>Department of Medicine III, Ludwig-Maximilian-University Hospital, Munich, Germany; <sup>2</sup>Clinical Cooperative Group Leukemia, Helmholtz Center, Munich, Germany; <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, NY; <sup>4</sup>Institute for Experimental Cancer Research, Comprehensive Cancer Center, University Hospital Ulm, Ulm, Germany; <sup>5</sup>Sanford-Burnham Medical Research Institute, San Diego, CA; <sup>6</sup>German Cancer Consortium, Heidelberg, Germany; <sup>7</sup>German Cancer Research Center, Heidelberg, Germany; <sup>8</sup>Institute for Pathology, Eberhard-Karls-University of Tübingen, Tübingen, Germany; <sup>9</sup>Molecular Hematology and Oncology, Department of Medicine IV, Halle University Hospital, Halle, Germany; <sup>10</sup>The Terry Fox Laboratory, BC Cancer Agency and the Department of Medicine, University of British Columbia, Vancouver, BC, Canada; and <sup>11</sup>Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany

## Key Points

- The conserved proline-rich region is essential for HOXB4 to amplify long-term hematopoietic stem cells without loss of homeostasis.
- Loss of this region increases leukemogenicity of HOXB4, altering its DNA-binding properties.

There is high interest in understanding the mechanisms that drive self-renewal of stem cells. HOXB4 is one of the few transcription factors that can amplify long-term repopulating hematopoietic stem cells in a controlled way. Here we show in mice that this characteristic of HOXB4 depends on a proline-rich sequence near the N terminus, which is unique among HOX genes and highly conserved in higher mammals. Deletion of this domain substantially enhanced the oncogenicity of HOXB4, inducing acute leukemia in mice. Conversely, insertion of the domain into Hoxa9 impaired leukemogenicity of this homeobox gene. These results indicate that proline-rich stretches attenuate the potential of stem cell active homeobox genes to acquire oncogenic properties. (*Blood*. 2017;129(3):319-323)

## Introduction

The ability to augment hematopoietic stem cell (HSC) numbers in vitro is critically dependent on our understanding of the molecular determinants of HSC self-renewal. One of the best studied transcriptional regulators of HSC self-renewal is *HOXB4*, which has been shown to induce a significant increase in the frequency of HSCs in human and murine systems by retrovirally engineered overexpression or protein delivery.<sup>1-6</sup> Despite being among the most potent known stimulators of HSC expansion, sustained overexpression of *Hoxb4* in vivo does not result in regeneration of HSC numbers above those in unmanipulated normal mice, suggesting that it does not override homeostatic control mechanisms regulating HSC numbers.<sup>1,4,7</sup> This observation is in line with data demonstrating that constitutive expression of *Hoxb4* is not overtly leukemogenic in the absence of cooperating genes such as *Meis1* in contrast to other *Hoxb* genes or *Hox* genes of the A cluster in mice.<sup>8,9</sup> The critical functional domains of *Hoxb4* that distinguish its overt effects on hematopoiesis from other Hox proteins are not fully

elucidated. We now demonstrate that the proline-rich domain near the N terminus in the *HOXB4* gene plays a key role in determining the largely nonleukemogenic stem cell amplificatory characteristics of HOXB4.

## Methods

## Retroviral constructs

The human *HOXB4* wild-type (wt; NM\_024015.4) and the *HOXB4*-ΔPRD complementary DNA (cDNA) were cloned at the *HpaI* site of the murine stem cell vector (MSCV) upstream of the internal ribosomal entry site (IRES) and the green fluorescent protein (GFP). A FLAG epitope was cloned in frame 5' of the *HOXB4* gene. The *HOXB4*-ΔPRD cDNA missing the nucleotides from position 229 to 360 of the coding DNA sequence (corresponding to amino acids 77-120) was synthesized and validated by Sanger sequencing. As a control, the MSCV


Submitted 5 April 2016; accepted 29 October 2016. Prepublished online as *Blood* First Edition paper, 8 November 2016; DOI 10.1182/blood-2016-04-706978.

The online version of this article contains a data supplement.

There is an Inside *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2017 by The American Society of Hematology



**Figure 1. Deletion of the highly conserved proline-rich region of HOXB4 induces acute myeloid leukemia (AML) in mice.** Multiple sequence alignments of (A) HOX paraloug group 4 proteins (reference sequences: HOXA4: gil133778294, HOXD4: gil23397672, HOXB4: gil12007115, HOXC4: gil11993919). (B) Multiple sequence alignment of HOXB4 proteins from different species: *Homo sapiens* NP\_076920.1, *Pan troglodytes* XP\_001173043.1, *Canis lupus* XP\_003639319, *Bos taurus* NP\_001071582.1, *Mus musculus* NP\_034589.3, *Rattus norvegicus* XP\_573184.1, *Gallus gallus* NP\_990624.1, and *Danio rerio* NP\_571193.1. The different colors correspond to the different amino acid classes. In the bottom box, the dendrogram shows the relationship distances (bar indicates genetic distances). (C) Survival curves of transplanted mice. P values of comparisons to HOXB4-ΔPRD<sub>229-360</sub> are indicated. (D) Histologic examinations of multiple organs infiltrated by leukemic blasts from a representative HOXB4-ΔPRD<sub>229-360</sub> diseased mouse. (E) Immunohistochemical examination of multiple organs infiltrated by leukemic blasts from a representative HOXB4-ΔPRD<sub>229-360</sub> diseased mouse that received a second transplant. H&E, hematoxylin and eosin; MPO, myeloperoxidase.

harboring only the IRES-enhanced GFP cassette was used. Point mutations in PBX interacting domain and homeodomain were introduced by polymerase chain reaction (PCR) following standard procedures. HOXB4 mutants with a partially reintroduced proline-rich domain (PRD) region were obtained by synthesis from GenScript. *Hoxa9*-wt cDNA (NM\_152739.3) was subcloned into MSCV enhanced green fluorescent protein, whereas *Hoxa9*-Pro-in<sub>423</sub>, *Hoxa9*-Pro-in<sub>813</sub>, *Hoxa9*-scramble (scr; random amino acid [aa] sequence), and *Hoxa9*-Pro-in<sub>false</sub> (same amino acids in random order) mutants were obtained by gene synthesis from GenScript and subcloned into the same vector. For *Meis1*, overexpression of the MSCV/YFP vector was used. Transcription profiling from HOXB4-transduced bone marrow (BM) was performed 48 hours after transduction after sorting for GFP. Chromatin immunoprecipitation (ChIP) analyses and transcription profiling on HOXB4-32D cells were performed on freshly transduced cells after sorting and after 2 to 3 weeks of liquid culture expansion.

## Results and discussion

### HOXB4 carries a 15-proline stretch, which is unique in the entire HOX gene cluster

To identify gene domains that are responsible for the stem cell amplification properties of HOXB4, we performed sequence alignments between HOXB4 and its paralogs and between HOXB4 and known leukemogenic Hox proteins. Intriguingly, a proline-rich region encoded by the nucleotides spanning positions 229 to 360 and corresponding to the amino acids 77 to 120 (HOXB4-ΔPRD<sub>229-360</sub>), and in particular the 15-proline stretch present in this region, were unique among the paralog group 4 and Hox B cluster members and absent in leukemogenic HOX proteins (Figure 1A; supplemental Figure 1A-B, available on the *Blood* Web site). There was a high conservation of the proline-rich region of HOXB4 among mice, humans, and higher mammals, but not among all vertebrate species (Figure 1B-C). On the basis of these results, we aimed to test the functional relevance of this unique HOXB4 domain by using a HOXB4 mutant lacking the proline-rich stretch (HOXB4-ΔPRD<sub>229-360</sub>).

### Deletion of the HOXB4-PRD<sub>229-360</sub> domain causes acute myeloid leukemia in mice

First, equal protein expression levels compared with HOXB4-wt and nuclear localization of the HOXB4-ΔPRD<sub>229-360</sub> mutant were documented (supplemental Figure 2A-C). Expression of HOXB4-ΔPRD<sub>229-360</sub> resulted in a significant increase in secondary colony formation compared with HOXB4-wt and the GFP control and augmented stem cell amplification compared with HOXB4-wt (supplemental Figure 3A-B; supplemental Table 1). Importantly, all mice transplanted with HOXB4-ΔPRD<sub>229-360</sub> overexpressing cells developed a significant shift toward myeloid engraftment and retransplantable AML without maturation according to the World Health Organization classification ( $n = 10$ ) in contrast to the HOXB4-wt and GFP control mice ( $P < .001$ ) (Figure 1C-E; supplemental Figure 3C-E; supplemental Table 2).<sup>10</sup> Sequencing of integration sites showed no recurrent integrations in diseased animals besides 1 CD68 integration in both the wt and the mutant experimental group (supplemental Table 3A-B).

The transforming activity of HOXB4-ΔPRD<sub>229-360</sub> was still dependent on DNA binding, but not on Pbx interaction, as shown by transplantation experiments of the double-mutant HOXB4-ΔPRD<sub>229-360</sub> harboring the homeodomain-inactivating mutation N211S (HOXB4-ΔPRD<sub>229-360</sub>-HD) and the double-mutant HOXB4-ΔPRD<sub>229-360</sub> harboring a point mutation inactivating the interaction with the Pbx

cofactor (W144A; HOXB4-ΔPRD-PBX interacting domain [PID]) (Figure 1C; supplemental Figure 2A; supplemental Table 2). Reinsertion of the 15-proline stretch present on the first half of the PRD alone or the second part of this domain enriched in SH3 domains into HOXB4-ΔPRD<sub>229-360</sub> (HOXB4-ΔPRD<sub>229-360</sub>-Pro-in<sub>aa77-86</sub> and HOXB4-ΔPRD<sub>229-360</sub>-SH3-in<sub>aa88-120</sub>) reduced secondary colony formation to the level of the wt HOXB4 (supplemental Figure 4A-B).


### Insertion of the proline-rich region into *Hoxa9* impairs its *Hoxa9*/Meis1-associated leukemogenicity

On the basis of these observations, we hypothesized that insertion of the proline-rich region of HOXB4 into a leukemogenic Hox gene such as *Hoxa9* will reduce its potential to induce AML.<sup>8,11,12</sup> We added the proline-encoding region at two positions of the *Hoxa9* wt sequence: first at the C-terminal end (*Hoxa9* Pro-in<sub>813</sub> mutant) and second between aa.141 and aa.142, resembling its natural position in the HOXB4 wt protein (*Hoxa9* Pro-in<sub>423</sub> mutant) (supplemental Figure 5A). Neither insertion induced major alterations in the predicted structure of the homeodomain (<http://iupred.enzim.hu>), decreased expression levels compared with *Hoxa9*-wt, or changed in vitro phenotypes (supplemental Figure 5B-E). In collaboration with Meis1, the *Hoxa9*-Pro-in<sub>423</sub> and to a lesser extent the *Hoxa9*-Pro-in<sub>813</sub> significantly impaired colony formation compared with the *Hoxa9*-scr control (supplemental Figure 5F). *Hoxa9*-Pro-in<sub>813</sub> moderately delayed leukemia onset by 11 days compared with *Hoxa9*-wt using c-kit<sup>+</sup> BM cells. *Hoxa9*-Pro-in<sub>423</sub> delayed leukemogenesis for more than 30 days by using *Hoxa9*-scr as a control in 5-fluorouracil treated BM cells (supplemental Table 4). Of note, *Hoxa9*-Pro-in<sub>423</sub> downregulated transcription of *c-myc* by 47% compared with the *Hoxa9*-scr control in cells derived from primary colony-forming cells, in line with our observation before the deletion of the proline-rich region in HOXB4 upregulated the *c-myc* signature. In addition, *Hoxa9*-Pro-in<sub>423</sub> downregulated other known *Hoxa9* targets such as *Runx1*, *C/ebpa*, and *Pu.1* in comparison with the control (data not shown).<sup>13,14</sup> To validate the effect of *Hoxa9*-Pro-in<sub>423</sub>, we performed limited dilution transplantations: expression of *Hoxa9*-Pro-in<sub>423</sub> induced a significant and 12-fold decrease in leukemic stem cell frequency compared with the *Hoxa9*-scr control ( $P < .05$ ; supplemental Table 5).

### Deletion of the proline-rich region induces gene expression associated with stemness and leukemic phenotype and grossly changes HOXB4 DNA-binding properties

HOXB4-ΔPRD<sub>229-360</sub> overexpression in BM progenitor cells induced significant gene expression changes (Figure 2A; supplemental Table 6A). Most of the genes differentially expressed in comparison with the GFP control did not overlap between HOXB4-wt and HOXB4-ΔPRD<sub>229-360</sub>, indicating that HOXB4-ΔPRD<sub>229-360</sub> generates primarily its own gene signature (Figure 2B-D; supplemental Table 6B). Within the set of uniquely deregulated genes, several genes were implicated in chromatin modification, kinase activity, gene expression control, undifferentiated cell stages, or *kras*- or *myc*-driven oncogenic signatures<sup>15-20</sup> (supplemental Figure 6). This was also observed in 32D myeloid cells (supplemental Figure 6B-D; supplemental Table 6C).

Deletion of PRD<sub>229-360</sub> grossly changed DNA binding of HOXB4-wt compared with HOXB4-ΔPRD<sub>229-360</sub> as assessed by ChIP sequencing with only 100 genes commonly bound by both proteins. Direct target genes (also affected in their expression levels) such as *Lmo2* and *Stat5* or genes such as *Gart*, *Nup85*, and *Eif2b3*, enriched in leukemic human subpopulations were uniquely bound by HOXB4-ΔPRD<sub>229-360</sub> (<https://gexc.stanford.edu>) (Figure 2E-G; supplemental Figures 6A-B and 7; supplemental Tables 7-9). In line with our



**Figure 2. HOXB4- $\Delta$ PRD<sub>229-360</sub> induces different DNA-binding and transcription program than HOXB4-wt.** (A) Volcano plot representing differentially expressed genes in BM progenitor cells overexpressing HOXB4- $\Delta$ PRD<sub>229-360</sub> in comparison with BM cells overexpressing HOXB4-wt. Log ratios of expression values for each gene for HOXB4- $\Delta$ PRD<sub>229-360</sub> mutant vs HOXB4-wt are plotted against  $-\log_{10}$  of *P* values. (B) Venn diagrams showing the overlap between genes commonly upregulated and downregulated in BM progenitor cells upon overexpression of HOXB4- $\Delta$ PRD<sub>229-360</sub> and HOXB4-wt in comparison with the GFP control. (C) Heat maps of genes differentially expressed between HOXB4- $\Delta$ PRD<sub>229-360</sub> and HOXB4-wt in comparison with the GFP control BM cells. (D) Heat map of genes differentially expressed between HOXB4- $\Delta$ PRD<sub>229-360</sub> and HOXB4-wt BM progenitor cells. (E) ChIP-sequencing analysis. Genomic distribution of binding sites for HOXB4-wt and HOXB4- $\Delta$ PRD<sub>229-360</sub> over the gene body, focused on the 2000 bp's upstream of the transcription start site and downstream of transcription end site. The intragenic distance between the transcription start site and transcription end site in the x-axis is indicated as percent of total gene body length. (F) Venn diagram showing genes bound by HOXB4 and HOXB4- $\Delta$ PRD<sub>229-360</sub> and differentially expressed in 32D cells. Genes bound and differentially expressed are indicated as overlap (direct targets). (G) Venn diagrams showing overlap between genes affected in their expression and genes bound by (left) HOXB4-wt and by (right) HOXB4- $\Delta$ PRD<sub>229-360</sub> in 32D cell line (supplemental Tables 7 and 8).

observation of an induction of a more primitive gene expression signature by HOXB4- $\Delta$ PRD<sub>229-360</sub>, there was a substantially higher overlap between HOXB4- $\Delta$ PRD<sub>229-360</sub> targets and HOXB4 targets described previously in primitive cells compared with HOXB4-wt (supplemental Figure 7B-C).<sup>21-23</sup> Direct targets were confirmed by quantitative PCR from independent ChIP experiments performed with a monoclonal anti-FLAG antibody (supplemental Figure 7E). Motif enrichment analysis of the ChIP targets indicated that HOXB4- $\Delta$ PRD<sub>229-360</sub> loses binding to known cofactors such as YY1 and USF1 (supplemental Figure 8).<sup>24,25</sup> Deletion of the proline-rich stretch also changed protein binding as assessed by FLAG-co-immunoprecipitation followed by mass spectrometry (supplemental Figure 9A-D; supplemental Table 10A-B). Twenty-one proteins were uniquely bound by the mutant and 152 proteins were uniquely bound by HOXB4-wt, the latter significantly enriched for proteins involved in chromatin modification (supplemental Figure 9E-G). Binding was confirmed for representative proteins by FLAG-co-immunoprecipitation (supplemental Figure 9H).

In summary, these data shed new light on the potential of evolutionary conserved proline-rich domains to control HSC population size within the *HOX* gene cluster.

## Acknowledgments

The authors thank Bianka Ksienzyk, Department of Internal Medicine III at Ludwig-Maximilian-University Hospital for

the excellent support in the fluorescence-activated cell sorting procedures, the coworkers at the animal facility of Helmholtz Zentrum (Munich, Germany) for their continuous assistance, S. Wiese for support in performing the mass spectrometry analysis at the Proteomics core facility of the Medical Faculty Ulm, and Alan Chramiec and Richard Koche at Memorial Sloan Kettering Cancer Center for assistance with the biostatistics analysis.

This study was supported by the C01 project of the Sonderforschungsbereich 1074 funded by the Deutsche Forschungsgemeinschaft (C.B., M.A.M., and N.M.V.).

## Authorship

Contribution: M.C., M.F.-B., and C.B. designed the study; K.R.H. helped establish the HOXB4- $\Delta$ PRD<sub>229-360</sub> mutant; M.A.M. and M.C. performed statistical analyses; M.C., M.A.M., and C.B. wrote the manuscript; and all authors analyzed and interpreted the data and reviewed and approved the final version of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Christian Buske, Institute of Experimental Cancer Research, Comprehensive Cancer Center Ulm, University of Ulm, Albert-Einstein-Allee 11, 89091 Ulm, Germany; e-mail: christian.buske@uni-ulm.de.

## References

- Sauvageau G, Thorsteinsdottir U, Eaves CJ, et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. *Genes Dev.* 1995; 9(14):1753-1765.
- Schiedlmeier B, Santos AC, Ribeiro A, et al. HOXB4's road map to stem cell expansion. *Proc Natl Acad Sci USA.* 2007;104(43):16952-16957.
- Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. *Cell.* 2002;109(1):39-45.
- Thorsteinsdottir U, Sauvageau G, Humphries RK. Enhanced in vivo regenerative potential of HOXB4-transduced hematopoietic stem cells with regulation of their pool size. *Blood.* 1999;94(8):2605-2612.
- Amsellem S, Pflumio F, Bardin D, et al. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. *Nat Med.* 2003;9(11):1423-1427.
- Krosil J, Austin P, Beslu N, Kroon E, Humphries RK, Sauvageau G. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. *Nat Med.* 2003;9(11):1428-1432.
- Antonchuk J, Sauvageau G, Humphries RK. HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation. *Exp Hematol.* 2001;29(9):1125-1134.
- Thorsteinsdottir U, Mamo A, Kroon E, et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. *Blood.* 2002;99(1):121-129.
- Zhang XB, Beard BC, Trobridge GD, et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. *J Clin Invest.* 2008;118(4):1502-1510.
- Kogan SC, Ward JM, Anver MR, et al; Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. *Blood.* 2002; 100(1):238-245.
- Thorne RM, Milne TA. Dangerous liaisons: cooperation between Pbx3, Meis1 and Hoxa9 in leukemia. *Haematologica.* 2015;100(7):850-853.
- Schnabel CA, Jacobs Y, Cleary ML. HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis. *Oncogene.* 2000;19(5):608-616.
- Huang Y, Sitwala K, Bronstein J, et al. Identification and characterization of Hoxa9 binding sites in hematopoietic cells. *Blood.* 2012; 119(2):388-398.
- Collins C, Wang J, Miao H, et al. C/EBP $\alpha$  is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis. *Proc Natl Acad Sci USA.* 2014; 111(27):9899-9904.
- Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. *Science.* 2002;298(5593):601-604.
- Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. *Cell Stem Cell.* 2008;2(4):333-344.
- McKinney-Freeman S, Cahan P, Li H, et al. The transcriptional landscape of hematopoietic stem cell ontogeny. *Cell Stem Cell.* 2012;11(5):701-714.
- Gal H, Amariglio N, Trakhtenbrot L, et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. *Leukemia.* 2006;20(12):2147-2154.
- Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. *Nat Med.* 2011; 17(9):1086-1093.
- Somerville TC, Matheny CJ, Spencer GJ, et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. *Cell Stem Cell.* 2009;4(2):129-140.
- Oshima M, Endoh M, Endo TA, et al. Genome-wide analysis of target genes regulated by HoxB4 in hematopoietic stem and progenitor cells developing from embryonic stem cells. *Blood.* 2011;117(15):e142-e150.
- Fan R, Bonde S, Gao P, et al. Dynamic HoxB4-regulatory network during embryonic stem cell differentiation to hematopoietic cells. *Blood.* 2012; 119(19):e139-e147.
- Lee HM, Zhang H, Schulz V, Tuck DP, Forget BG. Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells. *Blood.* 2010;116(5):720-730.
- Gilthorpe J, Vandromme M, Brend T, et al. Spatially specific expression of Hoxb4 is dependent on the ubiquitous transcription factor NFY. *Development.* 2002;129(16):3887-3899.
- Deng C, Li Y, Liang S, et al. USF1 and hSET1A mediated epigenetic modifications regulate lineage differentiation and HoxB4 transcription. *PLoS Genet.* 2013;9(6):e1003524.



**blood**<sup>®</sup>

2017 129: 319-323

doi:10.1182/blood-2016-04-706978 originally published  
online November 8, 2016

## **Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus**

Monica Cusan, Naidu M. Vegi, Medhanie A. Mulaw, Shiva Bamezai, Lisa M. Kaiser, Aniruddha J. Deshpande, Philipp A. Greif, Leticia Quintanilla-Fend, Stefanie Göllner, Carsten Müller-Tidow, Keith R. Humphries, Scott A. Armstrong, Wolfgang Hiddemann, Michaela Feuring-Buske and Christian Buske

---

Updated information and services can be found at:

<http://www.bloodjournal.org/content/129/3/319.full.html>

Articles on similar topics can be found in the following Blood collections

[Brief Reports](#) (1950 articles)

[Hematopoiesis and Stem Cells](#) (3454 articles)

---

Information about reproducing this article in parts or in its entirety may be found online at:

[http://www.bloodjournal.org/site/misc/rights.xhtml#repub\\_requests](http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>